1. Home
  2. TSI vs MIRM Comparison

TSI vs MIRM Comparison

Compare TSI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

HOLD

Current Price

$4.61

Market Cap

221.7M

Sector

Finance

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$90.21

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSI
MIRM
Founded
1987
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.7M
5.4B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
TSI
MIRM
Price
$4.61
$90.21
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$114.67
AVG Volume (30 Days)
308.5K
688.0K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
7.46%
N/A
EPS Growth
N/A
74.59
EPS
N/A
N/A
Revenue
N/A
$19,138,000.00
Revenue This Year
N/A
$24.61
Revenue Next Year
N/A
$21.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.57
$36.88
52 Week High
$5.06
$109.28

Technical Indicators

Market Signals
Indicator
TSI
MIRM
Relative Strength Index (RSI) 36.96 43.51
Support Level $4.58 $85.76
Resistance Level $4.96 $107.51
Average True Range (ATR) 0.04 4.07
MACD 0.01 -0.94
Stochastic Oscillator 27.62 19.09

Price Performance

Historical Comparison
TSI
MIRM

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: